INS NYC 2024 Program

Poster	Poster Session 02 Program Schedule 02/15/2024 08:00 am - 09:15 am Room: Shubert Complex (Posters 1-60) Poster Session 02: Aging \| MCI \| Neurodegenerative Disease - PART 1 Final Abstract #46 LAS-Face- Name Associative Memory Exam: Discriminant validity for the detection of associative memory disorders in people with mild cognitive impairment in Argentina. Greta Keller, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina Nicolas Corvalan, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina Agostina Carello, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina Micaela Arruabarrena, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina Ismael Calandri, Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, Netherlands Clara Vila-Castelar, Neuropsychologists at Massachusetts General Hospital, Harvard Medical School, Massachusetts, United States Ricardo Allegri, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina Yakeel Quiroz, Neuropsychologists at Massachusetts General Hospital, Harvard Medical School, Massachusetts, United States Lucia Crivelli, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina Category: MCI (Mild Cognitive Impairment) Keyword 1: neuropsychological assessment Keyword 2: mild cognitive impairment Objective: The Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) is a validated version of the test that has been used to detect subtle cognitive changes in cognitively unimpaired adults at increased risk for Alzheimer's disease (AD). Performance in this test has also been associated with markers of brain pathology in cognitively unimpaired older adults at increased risk for AD due to genetic factors or subjective cognitive decline (Papp et al., 2014;Vila-Castelar et al., 2020). However, this test has not yet been used for the detection of Mild Cognitive Impairment (MCI) in the Latin American population. This study aims to analyze the discriminative validity and diagnostic performance of the LAS-FNAME for the detection of verbal associative memory disorders in patients with MCI. Participants and Methods: We recruited 30 patients with MCI according to Petersen's criteria (2010) and 20 healthy controls matched by age, sex and educational level. All participants completed the LAS-FNAME, which consists of 12 learning trials of novel pairs of face-names (immediate learning), followed by a delayed recall condition, and a neuropsychological assessment that included the following measures: Montreal Cognitive Assessment (MoCA), Craft Story 21, Multifactorial Memory Questionnaire (MMQ-S) and a Functional Activity Questionnaire (FAQ). Results: MCI patients and controls did not differ in age, sex or education (p=0.25, p=0.54, p=0.54). The age range was 61 to 86 years (M=74.66; SD=6.65) and the education range was 7 to 18 years (M=14.63; SD=3.41). The LAS-FNAME showed an ability to discriminate against healthy controls from patients with MCI, both in its immediate (AUC = 0.81) and delayed (AUC = 0.79) conditions. The predictive ability was superior than a screening measure (MoCA, AUC=0.74). The sensitivity and specificity was 68.4% and 89.3% respectively. The LAS-FNAME also showed evidence of concurrent validity with a standard memory test (Craft Story 21) in both immediate (r=0.52, p<0.01) and delayed (r=0.63, p<0.01) conditions, and reliability was excellent (α=0.91). Conclusions: Performance on the LAS-FNAME was able to distinguish MCI patients from healthy controls, suggesting that the LAS-FNAME can detect early cognitive changes in prodromal stages of Alzheimer's disease in Latin American individuals with broad levels of formal education.

Poster

02/15/2024
08:00 am - 09:15 am
Room: Shubert Complex (Posters 1-60)

Poster Session 02: Aging | MCI | Neurodegenerative Disease - PART 1

Final Abstract #46

LAS-Face- Name Associative Memory Exam: Discriminant validity for the detection of associative memory disorders in people with mild cognitive impairment in Argentina.

Greta Keller, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina
Nicolas Corvalan, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina
Agostina Carello, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina
Micaela Arruabarrena, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina
Ismael Calandri, Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Clara Vila-Castelar, Neuropsychologists at Massachusetts General Hospital, Harvard Medical School, Massachusetts, United States
Ricardo Allegri, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina
Yakeel Quiroz, Neuropsychologists at Massachusetts General Hospital, Harvard Medical School, Massachusetts, United States
Lucia Crivelli, Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina

Category: MCI (Mild Cognitive Impairment)

Keyword 1: neuropsychological assessment
Keyword 2: mild cognitive impairment

Objective:

The Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) is a validated version of the test that has been used to detect subtle cognitive changes in cognitively unimpaired adults at increased risk for Alzheimer's disease (AD). Performance in this test has also been associated with markers of brain pathology in cognitively unimpaired older adults at increased risk for AD due to genetic factors or subjective cognitive decline (Papp et al., 2014;Vila-Castelar et al., 2020). However, this test has not yet been used for the detection of Mild Cognitive Impairment (MCI) in the Latin American population. This study aims to analyze the discriminative validity and diagnostic performance of the LAS-FNAME for the detection of verbal associative memory disorders in patients with MCI.

Participants and Methods:

We recruited 30 patients with MCI according to Petersen's criteria (2010) and 20 healthy controls matched by age, sex and educational level. All participants completed the LAS-FNAME, which consists of 12 learning trials of novel pairs of face-names (immediate learning), followed by a delayed recall condition, and a neuropsychological assessment that included the following measures: Montreal Cognitive Assessment (MoCA), Craft Story 21, Multifactorial Memory Questionnaire (MMQ-S) and a Functional Activity Questionnaire (FAQ).

Results:

MCI patients and controls did not differ in age, sex or education (p=0.25, p=0.54, p=0.54). The age range was 61 to 86 years (M=74.66; SD=6.65) and the education range was 7 to 18 years (M=14.63; SD=3.41). The LAS-FNAME showed an ability to discriminate against healthy controls from patients with MCI, both in its immediate (AUC = 0.81) and delayed (AUC = 0.79) conditions. The predictive ability was superior than a screening measure (MoCA, AUC=0.74). The sensitivity and specificity was 68.4% and 89.3% respectively. The LAS-FNAME also showed evidence of concurrent validity with a standard memory test (Craft Story 21) in both immediate (r=0.52, p<0.01) and delayed (r=0.63, p<0.01) conditions, and reliability was excellent (α=0.91).

Conclusions:

Performance on the LAS-FNAME was able to distinguish MCI patients from healthy controls, suggesting that the LAS-FNAME can detect early cognitive changes in prodromal stages of Alzheimer's disease in Latin American individuals with broad levels of formal education.